Skip to content

Role of Cryobiopsy in Diagnosis of Pleural Effusion

The Diagnostic Value of Cryobiopsy During Medical Thoracoscopy in Diagnosis of Pleural Effusion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03828903
Enrollment
60
Registered
2019-02-04
Start date
2020-03-10
Completion date
2021-10-10
Last updated
2021-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleural Effusion

Keywords

Cryobiopsy

Brief summary

The purpose of this study is to evaluate the feasibility, size and quality of the specimens obtained by cryoprobe in comparison to those specimens obtained by flexible forceps during medical thoracoscopy in diagnosis of pleural effusion.

Detailed description

* Medical thoracoscopy with single-port-of-entry technique will be performed in the bronchoscopy unit under local anesthesia and conscious sedation using midazolam (2 mg) or pethidin. * vertical incision will be made with the scalpel (usually near the midaxillary line), through the skin and subcutaneous tissue, appropriate to the size of the trocar to be used, usually of approximately 10 mm, parallel with and in the middle of the selected intercostal space. * Then the trocar will be inserted until the sudden release of resistance (after passing the costal pleura) is felt. * Under direct vision with the thoracoscope, introduction of pneumothorax will be performed, and all pleural fluid will be removed, and the pleural cavity will be inspected. * Suspicious areas will be biopsied through the working channel of the thoracoscope. * two to six biopsies of a suspicious pleural lesion will establish the diagnosis. Technique of pleural biopsy using cryotechnique: * The probe (ERBE Elektromedizin GmbH( Gesellschaft mit beschränkter Haftung) , Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization. * The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch. * carbon dioxide will be used as the cryogen gas for cryobiopsy * The frozen tissue is going to be extracted by gently pulling of the probe. * Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.

Interventions

DEVICECryoprobe

* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization. * The tip of the cryoprobe will be attached to suspicious part of parietal pleura . * The frozen tissue is going to be extracted by gently pulling of the probe. * Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture. * The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. * The biopsy sample will be released from the probe by thawing in the saline. * The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

\- 1. Unilateral moderate or massive exudative pleural effusion patients. 2. Undiagnosed pleural effusion after simple pleural fluid aspiration, cytology or blind (closed) pleural biopsy using Abram's needle. 3\. Age\>18 years old

Exclusion criteria

1. Transudative pleural effusion. 2. Exudative pleural effusion less than one third of hemithorax. 3. Presence of hemorrhagic diathesis (prothrombin concentration \<50% and platelet count \<80,000/mm 3). 4. Poor performance state (ECOG performance status \>4) as recommended in BTS (British thoracic society) guidelines 2010. 5. Sever uncontrollable cough, hypercapnia and sever respiratory distress. 6. Fibrothorax, excessive pleural adhesion. \-

Design outcomes

Primary

MeasureTime frameDescription
comparison between pleural biopsy specimens obtained by flexible forceps with those obtained with cryoprobe during medical thoracoscopy in diagnosis of pleural effusion.12 months1\_size of pleural biopsy obtained by cryoprobe in comparison to those obtained by flexible forceps (in millimeter).

Secondary

MeasureTime frameDescription
Complication assessment12 monthsTo evaluate the safety and occurrence of complication such as bleeding Number of patients with a certain degree of bleeding from biopsy site, described as: 1 = slight, self-limited, 2 = moderate, requiring electrocautery intervention, 3 = severe, requiring interruption of the procedure, chest tube drainage and intravenous fluid resuscitation .
assessment pleural fluid12 monthscomparison between the estimate of pleural effusion using chest ultrasound and actual amount after thoracoscpic drainage, measured in mililiters.
assessment of post procedure pain12 monthscomparison between meperidine and (midazolam &NSAIDs) in controlling pain post thoracoscopy.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026